Q-omics provides the consensus-scored TRMT10A profile across patient tissues and cancer cell-line models. TRMT10A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRMT10A is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TRMT10A RNA expression shows 19,768 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, THCA, and UVM as cancer lineages where TRMT10A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT10A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT10A survival associations across molecular data types. TRMT10A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT10A RNA expression–survival associations across cancer types. High TRMT10A expression shows unfavorable associations in KIRP, LUAD, UVM and KICH, but favorable associations in KIRC and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TRMT10A RNA expression.
This table summarizes TRMT10A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRMT10A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT10A shows lower tumor expression in THCA, KIRC, KIRP and KICH and higher tumor expression in BRCA and STAD. The THCA box plot shows higher TRMT10A RNA expression in normal versus tumor tissue (log2 FC = −1.058, t-test p < 0.001).
This table shows molecular features associated with TRMT10A in patient tissues and cancer cell lines. In patient samples, TRMT10A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT10A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
